Cargando…

Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future

Glioma is the most common malignant intracranial tumor and exhibits diffuse metastasis and a high recurrence rate. The invasive property of glioma results from cell detachment. Anoikis is a special form of apoptosis that is activated upon cell detachment. Resistance to anoikis has proven to be a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhengyang, Fang, Chaoyou, Xu, Houshi, Yuan, Ling, Du, Yichao, Ni, Yunjia, Xu, Yuanzhi, Shao, Anwen, Zhang, Anke, Lou, Meiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423707/
https://www.ncbi.nlm.nih.gov/pubmed/36046036
http://dx.doi.org/10.3389/fonc.2022.976557
_version_ 1784778079243075584
author Zhu, Zhengyang
Fang, Chaoyou
Xu, Houshi
Yuan, Ling
Du, Yichao
Ni, Yunjia
Xu, Yuanzhi
Shao, Anwen
Zhang, Anke
Lou, Meiqing
author_facet Zhu, Zhengyang
Fang, Chaoyou
Xu, Houshi
Yuan, Ling
Du, Yichao
Ni, Yunjia
Xu, Yuanzhi
Shao, Anwen
Zhang, Anke
Lou, Meiqing
author_sort Zhu, Zhengyang
collection PubMed
description Glioma is the most common malignant intracranial tumor and exhibits diffuse metastasis and a high recurrence rate. The invasive property of glioma results from cell detachment. Anoikis is a special form of apoptosis that is activated upon cell detachment. Resistance to anoikis has proven to be a protumor factor. Therefore, it is suggested that anoikis resistance commonly occurs in glioma and promotes diffuse invasion. Several factors, such as integrin, E-cadherin, EGFR, IGFR, Trk, TGF-β, the Hippo pathway, NF-κB, eEF-2 kinase, MOB2, hypoxia, acidosis, ROS, Hsp and protective autophagy, have been shown to induce anoikis resistance in glioma. In our present review, we aim to summarize the underlying mechanism of resistance and the therapeutic potential of these molecules.
format Online
Article
Text
id pubmed-9423707
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94237072022-08-30 Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future Zhu, Zhengyang Fang, Chaoyou Xu, Houshi Yuan, Ling Du, Yichao Ni, Yunjia Xu, Yuanzhi Shao, Anwen Zhang, Anke Lou, Meiqing Front Oncol Oncology Glioma is the most common malignant intracranial tumor and exhibits diffuse metastasis and a high recurrence rate. The invasive property of glioma results from cell detachment. Anoikis is a special form of apoptosis that is activated upon cell detachment. Resistance to anoikis has proven to be a protumor factor. Therefore, it is suggested that anoikis resistance commonly occurs in glioma and promotes diffuse invasion. Several factors, such as integrin, E-cadherin, EGFR, IGFR, Trk, TGF-β, the Hippo pathway, NF-κB, eEF-2 kinase, MOB2, hypoxia, acidosis, ROS, Hsp and protective autophagy, have been shown to induce anoikis resistance in glioma. In our present review, we aim to summarize the underlying mechanism of resistance and the therapeutic potential of these molecules. Frontiers Media S.A. 2022-08-15 /pmc/articles/PMC9423707/ /pubmed/36046036 http://dx.doi.org/10.3389/fonc.2022.976557 Text en Copyright © 2022 Zhu, Fang, Xu, Yuan, Du, Ni, Xu, Shao, Zhang and Lou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Zhengyang
Fang, Chaoyou
Xu, Houshi
Yuan, Ling
Du, Yichao
Ni, Yunjia
Xu, Yuanzhi
Shao, Anwen
Zhang, Anke
Lou, Meiqing
Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title_full Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title_fullStr Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title_full_unstemmed Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title_short Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future
title_sort anoikis resistance in diffuse glioma: the potential therapeutic targets in the future
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423707/
https://www.ncbi.nlm.nih.gov/pubmed/36046036
http://dx.doi.org/10.3389/fonc.2022.976557
work_keys_str_mv AT zhuzhengyang anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT fangchaoyou anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT xuhoushi anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT yuanling anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT duyichao anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT niyunjia anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT xuyuanzhi anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT shaoanwen anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT zhanganke anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture
AT loumeiqing anoikisresistanceindiffusegliomathepotentialtherapeutictargetsinthefuture